Smart Design: Integrating Artificial Intelligence and Gene Editing for Advanced mRNA Therapeutics

Abstract

Artificial intelligence (AI) and gene editing are increasingly being applied to the design and evaluation of mRNA therapeutics. Although mRNA-based medicines have achieved clear clinical impact in vaccination, broader applications remain limited by mRNA instability, delivery barriers, tissue selectivity, and unwanted immunogenicity. This review examines how AI and gene editing can be combined to address these constraints. AI-based models support predictive optimization of untranslated regions, codon usage, secondary structure, and lipid nanoparticle (LNP) formulations, thereby improving the efficiency of sequence and delivery-system design. In parallel, CRISPR-Cas (clustered regularly interspaced short palindromic repeats-associated proteins) systems, base editors, and emerging RNA-editing tools provide platforms for disease modeling, target validation, and functional testing of mRNA-based interventions. We emphasize that the value of this convergence lies in iterative workflows: gene-editing screens generate quantitative datasets for model training, whereas AI helps prioritize editing strategies, guide sequence refinement, and improve delivery design. We also summarize representative applications, translational limitations, and prospects for closed-loop AI-gene editing platforms. Overall, the integration of computational prediction with programmable genome and RNA engineering may support more precise, adaptable, and clinically translatable mRNA therapeutics.

Keywords

artificial intelligence / gene editing / lipid nanoparticles / mRNA therapeutics / precision medicine

References

[1] C. Graña, L. Ghosn, T. Evrenoglou, et al., “Efficacy and Safety of COVID-19 Vaccines,” The Cochrane Database of Systematic Reviews 12, no. 12 (2022): 015477.

[2] S. P. Teo, “Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273,” Journal of Pharmacy Practice 35, no. 6 (2022): 947–951.

[3] N. Pardi and F. Krammer, “mRNA Vaccines for Infectious Diseases - Advances, Challenges and Opportunities,” Nature Reviews Drug Discovery 23, no. 11 (2024): 838–861.

[4] H. Parhiz, E. N. Atochina-Vasserman, and D. Weissman, “mRNA-Based Therapeutics: Looking Beyond COVID-19 Vaccines,” Lancet 403, no. 10432 (2024): 1192–1204.

[5] Y. Shi, M. Shi, Y. Wang, and J. You, “Progress and Prospects of mRNA-Based Drugs in Pre-Clinical and Clinical Applications,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 322.

[6] K. Y. Leong, S. K. Tham, and C. L. Poh, “Revolutionizing Immunization: A Comprehensive Review of mRNA Vaccine Technology and Applications,” Virology Journal 22, no. 1 (2025): 71.

[7] M. A. Ige, X. Ren, Y. Yang, et al., “mRNA Therapeutics: Transforming Medicine Through Innovation in Design, Delivery, and Disease Treatment,” Molecular Therapy. Nucleic Acids 36, no. 4 (2025): 102721.

[8] C. Fougeroux, S. H. Hagen, L. Goksøyr, et al., “A Modular mRNA Vaccine Platform Encoding Antigen-Presenting Capsid Virus-Like Particles Enhances the Immunogenicity of the Malaria Antigen Pfs25,” Nature Nanotechnology 20, no. 6 (2025): 845–855.

[9] G. Boël, R. Letso, H. Neely, et al., “Codon Influence on Protein Expression in E. Coli Correlates With mRNA Levels,” Nature 529, no. 7586 (2016): 358–363.

[10] Y. Liu, Q. Yang, and F. Zhao, “Synonymous But Not Silent: The Codon Usage Code for Gene Expression and Protein Folding,” Annual Review of Biochemistry 90 (2021): 375–401.

[11] A. J. Grippin, C. Marconi, S. Copling, et al., “SARS-CoV-2 mRNA Vaccines Sensitize Tumours to Immune Checkpoint Blockade,” Nature 647, no. 8089 (2025): 488–497.

[12] H. Fu, Y. Liang, X. Zhong, et al., “Codon Optimization With Deep Learning to Enhance Protein Expression,” Scientific Reports 10, no. 1 (2020): 17617.

[13] N. Pardi, M. J. Hogan, F. W. Porter, and D. Weissman, “mRNA Vaccines - a New Era in Vaccinology,” Nature Reviews Drug Discovery 17, no. 4 (2018): 261–279.

[14] S. Chatterjee, E. Kon, P. Sharma, and D. Peer, “Endosomal Escape: A Bottleneck for LNP-Mediated Therapeutics,” Proceedings of the National Academy of Sciences 121, no. 11 (2024): e2307800120.

[15] Z. R. Lu and D. Sun, “Mechanism of pH-Sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery,” Pharmaceutical Research 42, no. 7 (2025): 1065–1077.

[16] X. Hou, T. Zaks, R. Langer, and Y. Dong, “Lipid Nanoparticles for mRNA Delivery,” Nature Reviews Materials 6, no. 12 (2021): 1078–1094.

[17] S. S. Pati, S. Dhal, R. Pattnaik, S. Tripathy, and S. Kumar, “mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives,” Current Medical Science 45, no. 5 (2025): 985–1002.

[18] M. Zitnik, “AI-Enabled Drug Discovery Reaches Clinical Milestone,” Nature Medicine 31, no. 8 (2025): 2490–2491.

[19] K. Zhang, X. Yang, Y. Wang, et al., “Artificial Intelligence in Drug Development,” Nature Medicine 31, no. 1 (2025): 45–59.

[20] I. Filella-Merce, A. Molina, L. Díaz, et al., “Optimizing Drug Design by Merging Generative AI With a Physics-Based Active Learning Framework,” Communications Chemistry 8 (2025): 238.

[21] D. B. Catacutan, J. Alexander, A. Arnold, and J. M. Stokes, “Machine Learning in Preclinical Drug Discovery,” Nature Chemical Biology 20, no. 8 (2024): 960–973.

[22] H. Zhang, H. Liu, Y. Xu, et al., “Deep Generative Models Design mRNA Sequences With Enhanced Translational Capacity and Stability,” Science 390, no. 6773 (2025): eadr8470.

[23] Y. Xiong, A. Wang, Y. Kang, C. Shen, C. Y. Hsieh, and T. Hou, “mRNABERT: Advancing mRNA Sequence Design With a Universal Language Model and Comprehensive Dataset,” Nature Communications 16, no. 1 (2025): 10371.

[24] J. Witten, I. Raji, R. S. Manan, et al., “Artificial Intelligence-Guided Design of Lipid Nanoparticles for Pulmonary Gene Therapy,” Nature Biotechnology 43, no. 11 (2025): 1790–1799.

[25] H. A. Rees and D. R. Liu, “Base Editing: Precision Chemistry on the Genome and Transcriptome of Living Cells,” Nature Reviews Genetics 19, no. 12 (2018): 770–788.

[26] D. K. Lam, P. R. Feliciano, A. Arif, et al., “Improved Cytosine Base Editors Generated From Tada Variants,” Nature Biotechnology 41, no. 5 (2023): 686–697.

[27] M. E. Neugebauer, A. Hsu, M. Arbab, et al., “Evolution of an Adenine Base Editor Into a Small, Efficient Cytosine Base Editor With Low Off-Target Activity,” Nature Biotechnology 41, no. 5 (2023): 673–685.

[28] J. Popovitz, R. Sharma, R. Hoshyar, B. Soo Kim, N. Murthy, and K. Lee, “Gene Editing Therapeutics Based on mRNA Delivery,” Advanced Drug Delivery Reviews 200 (2023): 115026.

[29] C. J. Vanhinsbergh, A. Criscuolo, J. N. Sutton, et al., “Characterization and Sequence Mapping of Large RNA and mRNA Therapeutics Using Mass Spectrometry,” Analytical Chemistry 94, no. 20 (2022): 7339–7349.

[30] S. M. Castillo-Hair and G. Seelig, “Machine Learning for Designing Next-Generation mRNA Therapeutics,” Accounts of Chemical Research 55, no. 1 (2022): 24–34.

[31] J. H. Lobel and N. T. Ingolia, “Deciphering Disordered Regions Controlling mRNA Decay in High-Throughput,” Nature 642, no. 8068 (2025): 805–813.

[32] X. Duan, J. Chen, S. Jiang, et al., “A Novel Machine Learning Framework-Based Rapid Screening of Ionizable Lipids in LNPs for Highly-Efficient mRNA Expression,” Acta Pharmaceutica Sinica B (2025), https://doi.org/10.1016/j.apsb.2025.10.040.

[33] L. Jin, Y. Zhou, S. Zhang, and S. J. Chen, “mRNA Vaccine Sequence and Structure Design and Optimization: Advances and Challenges,” Journal of Biological Chemistry 301, no. 1 (2025): 108015.

[34] H. Zhang, L. Zhang, A. Lin, et al., “Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity,” Nature 621, no. 7978 (2023): 396–403.

[35] S. He, B. Gao, R. Sabnis, and Q. Sun, “RNAdegformer: Accurate Prediction of mRNA Degradation at Nucleotide Resolution With Deep Learning,” Briefings in Bioinformatics 24, no. 1 (2023): bbac581.

[36] F. Villanueva-Flores, J. I. Sanchez-Villamil, and I. Garcia-Atutxa, “AI-Driven Epitope Prediction: A Systematic Review, Comparative Analysis, and Practical Guide for Vaccine Development,” NPJ Vaccines 10, no. 1 (2025): 207.

[37] M. Barazesh, M. Abbasi, M. Mohammadi, et al., “Bioinformatics Analysis to Design a Multi-Epitope mRNA Vaccine Against S. Agalactiae Exploiting Pathogenic Proteins,” Scientific Reports 14, no. 1 (2024): 28294.

[38] Y. Liu, J. Gao, X. Zhang, and X. Fang, “Joint Design of 5' Untranslated Region and Coding Sequence of mRNA,” arXiv (2024): 241020781 https://doi.org/10.48550/arXiv.2410.20781.

[39] A. T. Riley, J. M. Robson, A. Ulanova, and A. A. Green, “Generative and Predictive Neural Networks for the Design of Functional RNA Molecules,” Nature Communications 16, no. 1 (2025): 4155.

[40] Z. Gong, Z. Jiang, W. Gao, D. Zhuo, and L. Ma A New Deep-Learning-Based Approach for mRNA Optimization: High Fidelity, Computation Efficiency, and Multiple Optimization Factors. arXiv preprint arXiv. 2025; 250523862.

[41] Z. Yang, P. Bogdan, and S. Nazarian, “An in Silico Deep Learning Approach to Multi-Epitope Vaccine Design: A SARS-CoV-2 Case Study,” Scientific Reports 11, no. 1 (2021): 3238.

[42] S. Li, S. Moayedpour, R. Li, et al., “CodonBERT Large Language Model for mRNA Vaccines,” Genome Research 34, no. 7 (2024): 1027–1035.

[43] B. Rajbanshi and A. Guruacharya, “Codongpt: Reinforcement Learning on a Generative Language Model Enables Scalable mRNA Design,” Nucleic Acids Research 53, no. 22 (2025): gkaf1345.

[44] L. A. Rojas, Z. Sethna, K. C. Soares, et al., “Personalized RNA Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer,” Nature 618, no. 7963 (2023): 144–150.

[45] M. U. Muckenthaler, B. Galy, and M. W. Hentze, “Systemic Iron Homeostasis and the Iron-Responsive Element/Iron-Regulatory Protein (IRE/IRP) Regulatory Network,” Annual Review of Nutrition 28 (2008): 197–213.

[46] M. Kozak, “Regulation of Translation via mRNA Structure in Prokaryotes and Eukaryotes,” Gene 361 (2005): 13–37.

[47] D. R. Morris and A. P. Geballe, “Upstream Open Reading Frames as Regulators of mRNA Translation,” Molecular and Cellular Biology 20, no. 23 (2000): 8635–8642.

[48] H. Gingold and Y. Pilpel, “Determinants of Translation Efficiency and Accuracy,” Molecular Systems Biology 7 (2011): MSB201114.

[49] W. E. Walden, A. I. Selezneva, J. Dupuy, et al., “Structure of Dual Function Iron Regulatory Protein 1 Complexed With Ferritin IRE-RNA,” Science 314, no. 5807 (2006): 1903–1908.

[50] A. Frankish, S. Carbonell-Sala, M. Diekhans, et al., “GENCODE: Reference Annotation for the Human and Mouse Genomes in 2023,” Nucleic Acids Research 51, no. D1 (2023): D942–D949.

[51] A. Karollus, Ž. Avsec, and J. Gagneur, “Predicting Mean Ribosome Load for 5'UTR of Any Length Using Deep Learning,” PLoS Computational Biology 17, no. 5 (2021): e1008982.

[52] P. J. Sample, B. Wang, D. W. Reid, et al., “Human 5′ UTR Design and Variant Effect Prediction From a Massively Parallel Translation Assay,” Nature Biotechnology 37, no. 7 (2019): 803–809.

[53] J. Cao, E. M. Novoa, Z. Zhang, et al., “High-Throughput 5’ UTR Engineering for Enhanced Protein Production in Non-Viral Gene Therapies,” Nature Communications 12, no. 1 (2021): 4138.

[54] W. Zheng, J. H. C. Fong, Y. K. Wan, et al., “Translation Rate Prediction and Regulatory Motif Discovery With Multi-Task Learning,” Research in Computational Molecular Biology 13976 (2023): 139–154.

[55] W. Zheng, J. H. C. Fong, Y. K. Wan, et al., “Discovery of Regulatory Motifs in 5′ Untranslated Regions Using Interpretable Multi-Task Learning Models,” Cell Systems 14, no. 12 (2023): 1103–1112.e6.

[56] S. Barazandeh, F. Ozden, A. Hincer, U. O. S. Seker, and A. E. Cicek, “UTRGAN: Learning to Generate 5′ UTR Sequences for Optimized Translation Efficiency and Gene Expression,” Bioinformatics Advances 5, no. 1 (2025): vbaf134.

[57] X. Tang, M. Huo, Y. Chen, et al., “A Novel Deep Generative Model for mRNA Vaccine Development: Designing 5′ UTRs With N1-Methyl-Pseudouridine Modification,” Acta Pharmaceutica Sinica B 14, no. 4 (2024): 1814–1826.

[58] L. Wei, S. Li, P. Zhang, et al., “Characterizing MicroRNA-Mediated Modulation of Gene Expression Noise and Its Effect on Synthetic Gene Circuits,” Cell Reports 36, no. 8 (2021): 109573.

[59] S. D. Findlay, L. Romo, and C. B. Burge, “Quantifying Negative Selection in Human 3′ UTRs Uncovers Constrained Targets of RNA-Binding Proteins,” Nature Communications 15, no. 1 (2024): 85.

[60] B. Bae and P. Miura, “Emerging Roles for 3′ UTRs in Neurons,” International Journal of Molecular Sciences 21, no. 10 (2020): 3413, https://doi.org/10.3390/ijms21103413.

[61] O. Yaish and Y. Orenstein, “Computational Modeling of mRNA Degradation Dynamics Using Deep Neural Networks,” Bioinformatics 38, no. 4 (2022): 1087–1101.

[62] Z. Luo, J. Zhang, J. Fei, and S. Ke, “Deep Learning Modeling m(6)A Deposition Reveals the Importance of Downstream Cis-Element Sequences,” Nature Communications 13, no. 1 (2022): 2720.

[63] Y. Yang, G. Li, K. Pang, W. Cao, Z. Zhang, and X. Li, “Deciphering 3'UTR Mediated Gene Regulation Using Interpretable Deep Representation Learning,” Adv Sci (Weinh) 11, no. 39 (2024): e2407013.

[64] T. Nieuwkoop, B. R. Terlouw, K. G. Stevens, et al., “Revealing Determinants of Translation Efficiency via Whole-Gene Codon Randomization and Machine Learning,” Nucleic Acids Research 51, no. 5 (2023): 2363–2376.

[65] R. Sabi, R. Volvovitch Daniel, and T. Tuller, “stAIcalc: tRNA Adaptation Index Calculator Based on Species-Specific Weights,” Bioinformatics 33, no. 4 (2017): 589–591.

[66] D. Sharma and S. Chakraborty, “RNA Editing Sites and Triplet Usage in Exomes of Bat RNA Virus Genomes of the Family Paramyxoviridae,” Microbial Pathogenesis 194 (2024): 106796.

[67] R. Jain, A. Jain, E. Mauro, K. LeShane, and D. Densmore, “ICOR: Improving Codon Optimization With Recurrent Neural Networks,” BMC Bioinformatics 24, no. 1 (2023): 132.

[68] Z. Ren, L. Jiang, Y. Di, et al., “CodonBERT: A BERT-Based Architecture Tailored for Codon Optimization Using the Cross-Attention Mechanism,” Bioinformatics 40, no. 7 (2024): btae330, https://doi.org/10.1093/bioinformatics/btae330.

[69] Y. Li, F. Wang, J. Yang, et al., “Deep Generative Optimization of mRNA Codon Sequences for Enhanced mRNA Translation and Therapeutic Efficacy,” Nature Communications 16, no. 1 (2025): 9957.

[70] X. Hou, J. Shi, and Y. Xiao, “mRNA Medicine: Recent Progresses in Chemical Modification, Design, and Engineering,” Nano Research 17, no. 10 (2024): 9015–9030.

[71] K. Toyama, T. Eto, K. Takazawa, et al., “DS-5670a, a Novel mRNA-Encapsulated Lipid Nanoparticle Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2: Results From a Phase 2 Clinical Study,” Vaccine 41, no. 38 (2023): 5525–5534.

[72] S. Karmaker, P. D. Rosales, B. Tirumuruhan, A. Viravalli, and N. Boehnke, “More Than a Delivery System: The Evolving Role of Lipid-Based Nanoparticles,” Nanoscale 17, no. 19 (2025): 11864–11893.

[73] K. Su, J. Qiu, T. Xu, and S. Liu, “Artificial Intelligence-Guided Design of Lipid Nanoparticles for mRNA Delivery,” Acta Pharmaceutica Sinica B 16, no. 2 (2026): 709–727.

[74] Y. Feng, W. Tai, P. Huang, et al., “Albumin-Recruiting Lipid Nanoparticle Potentiates the Safety and Efficacy of mRNA Vaccines by Avoiding Liver Accumulation,” Nature Materials 24, no. 11 (2025): 1826–1839.

[75] S. Wu, L. Shi, K. Su, et al., “Carbonate-Bearing Ionizable Lipids for mRNA Delivery to Splenic NK Cells,” Journal of the American Chemical Society 147, no. 32 (2025): 28665–28673.

[76] Y. Ma, S. Li, X. Lin, and Y. Chen, “A Perspective of Lipid Nanoparticles for RNA Delivery,” Exploration 4, no. 6 (2024): 20230147.

[77] Y. Zhang, X. Zhang, Y. Gao, and S. Liu, “Principles of Lipid Nanoparticle Design for mRNA Delivery,” BMEMat 3, no. 1 (2025): e12116.

[78] X. Han, H. Zhang, K. Butowska, et al., “An Ionizable Lipid Toolbox for RNA Delivery,” Nature Communications 12, no. 1 (2021): 7233.

[79] Q. Cheng, T. Wei, L. Farbiak, L. T. Johnson, S. A. Dilliard, and D. J. Siegwart, “Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery and CRISPR-Cas Gene Editing,” Nature Nanotechnology 15, no. 4 (2020): 313–320.

[80] H. Li, Y. Zhao, and C. Xu, “Machine Learning Techniques for Lipid Nanoparticle Formulation,” Nano Convergence 12, no. 1 (2025): 35.

[81] L. Gurba-Bryśkiewicz, W. Maruszak, D. A. Smuga, K. Dubiel, and M. Wieczorek, “Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery,” Biomedicines 11, no. 10 (2023): 2752.

[82] Y. Xie, J. Guo, J. Hu, et al., “A Factorial Design-Optimized Microfluidic LNP Vaccine Elicits Potent Magnesium-Adjuvating Cancer Immunotherapy,” Materials Today Bio 32 (2025): 101703.

[83] L. Liu, J. H. Kim, Z. Li, et al., “PEGylated Lipid Screening, Composition Optimization, and Structure-Activity Relationship Determination for Lipid Nanoparticle-Mediated mRNA Delivery,” Nanoscale 17, no. 18 (2025): 11329–11344.

[84] M. Hammel, Y. Fan, A. Sarode, et al., “Correlating the Structure and Gene Silencing Activity of Oligonucleotide-Loaded Lipid Nanoparticles Using Small-Angle X-Ray Scattering,” ACS Nano 17, no. 12 (2023): 11454–11465.

[85] D. M. Dhumal, P. D. Patil, R. V. Kulkarni, and K. G. Akamanchi, “Experimentally Validated QSAR Model for Surface pK (a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics,” ACS Omega 5, no. 49 (2020): 32023–32031.

[86] K. A. Whitehead, J. R. Dorkin, A. J. Vegas, et al., “Degradable Lipid Nanoparticles With Predictable In Vivo siRNA Delivery Activity,” Nature Communications 5 (2014): 4277.

[87] C. Tang, Y. Zhang, B. Li, et al., “Modular Design of Lipopeptide-Based Organ-Specific Targeting (POST) Lipid Nanoparticles for Highly Efficient RNA Delivery,” Advanced Materials 37, no. 11 (2025): e2415643.

[88] G. Kumar and A. M. Ardekani, “Machine-Learning Framework to Predict the Performance of Lipid Nanoparticles for Nucleic Acid Delivery,” ACS Applied Bio Materials 8, no. 5 (2025): 3717–3727.

[89] Y. Yuan, Y. Li, G. Li, et al., “Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics,” Molecular Pharmaceutics 22, no. 3 (2025): 1142–1159.

[90] K. Amoako, A. Mokhammad, A. Malik, et al., “Enhancing Nucleic Acid Delivery by the Integration of Artificial Intelligence Into Lipid Nanoparticle Formulation,” Frontiers in Medical Technology 7 (2025): 1591119.

[91] S. Imani, X. Li, K. Chen, et al., “Computational Biology and Artificial Intelligence in mRNA Vaccine Design for Cancer Immunotherapy,” Frontiers in Cellular and Infection Microbiology 14 (2024): 1501010.

[92] J. Basso, M. Mendes, J. Silva, et al., “Sorting Hidden Patterns in Nanoparticle Performance for Glioblastoma Using Machine Learning Algorithms,” International Journal of Pharmaceutics 592 (2021): 120095.

[93] A. Chan, A. R. Kirtane, Q. R. Qu, et al., “Designing Lipid Nanoparticles Using a Transformer-Based Neural Network,” Nature Nanotechnology 20, no. 10 (2025): 1491–1501.

[94] L. Lam, S. Watson, Y. Ramaswamy, and G. Singh, “High-Throughput Strategies for Streamlining Lipid Nanoparticle Development Pipeline,” Advanced Science 12, no. 42 (2025): e11551.

[95] S. H. Bae, H. Choi, J. Lee, et al., “Rational Design of Lipid Nanoparticles for Enhanced mRNA Vaccine Delivery via Machine Learning,” Small 21, no. 8 (2025): e2405618.

[96] W. Wang, K. Chen, T. Jiang, et al., “Artificial Intelligence-Driven Rational Design of Ionizable Lipids for mRNA Delivery,” Nature Communications 15, no. 1 (2024): 10804.

[97] B. Li, I. O. Raji, A. G. R. Gordon, et al., “Accelerating Ionizable Lipid Discovery for mRNA Delivery Using Machine Learning and Combinatorial Chemistry,” Nature Materials 23, no. 7 (2024): 1002–1008.

[98] Y. Xu, S. Ma, H. Cui, et al., “AGILE Platform: A Deep Learning Powered Approach to Accelerate LNP Development for mRNA Delivery,” Nature Communications 15, no. 1 (2024): 6305.

[99] L. Miao, L. Li, Y. Huang, et al., “Delivery of mRNA Vaccines With Heterocyclic Lipids Increases Anti-Tumor Efficacy by STING-Mediated Immune Cell Activation,” Nature Biotechnology 37, no. 10 (2019): 1174–1185.

[100] Y. Wang, X. Liu, H. Yang, et al., “Ugi-Reaction-Derived Ionizable Lipids With Cyclic Tertiary Amine Heads Enable Spleen-Targeted mRNA Delivery,” Biomaterials Science 13, no. 16 (2025): 4494–4501.

[101] J. Li, J. Hu, D. Jin, et al., “High-Throughput Synthesis and Optimization of Ionizable Lipids Through A(3) Coupling for Efficient mRNA Delivery,” Journal of Nanobiotechnology 22, no. 1 (2024): 672.

[102] X. Shan, Y. Cai, B. Zhu, et al., “Rational Strategies for Improving the Efficiency of Design and Discovery of Nanomedicines,” Nature Communications 15, no. 1 (2024): 9990.

[103] M. A. Fouad, H. Abdel-Hamid, and M. S. Ayoup, “Two Decades of Recent Advances of Ugi Reactions: Synthetic and Pharmaceutical Applications,” RSC Advances 10, no. 70 (2020): 42644–42681.

[104] W. Wang, S. Feng, Z. Ye, H. Gao, J. Lin, and D. Ouyang, “Prediction of Lipid Nanoparticles for mRNA Vaccines by the Machine Learning Algorithm,” Acta Pharmaceutica Sinica B 12, no. 6 (2022): 2950–2962.

[105] M. Rafiei, A. Shojaei, and Y. Chau, “Machine Learning-Assisted Design of Immunomodulatory Lipid Nanoparticles for Delivery of mRNA to Repolarize Hyperactivated Microglia,” Drug Delivery 32, no. 1 (2025): 2465909.

[106] B. I. Hanafy, M. J. Munson, R. Soundararajan, et al., “Advancing Cellular-Specific Delivery: Machine Learning Insights Into Lipid Nanoparticles Design and Cellular Tropism,” Advanced Healthcare Materials 14 (2025): e2500383.

[107] A. Abostait, M. Abdelkarim, Z. Bao, et al., “Optimizing Lipid Nanoparticles for Fetal Gene Delivery in Vitro, Ex Vivo, and Aided With Machine Learning,” Journal of Controlled Release 376 (2024): 678–700.

[108] H. Gao, S. Kan, Z. Ye, et al., “Development of in Silico Methodology for siRNA Lipid Nanoparticle Formulations,” Chemical Engineering Journal 442 (2022): 136310.

[109] L. Cheng, Y. Zhu, J. Ma, et al., “Machine Learning Elucidates Design Features of Plasmid Deoxyribonucleic Acid Lipid Nanoparticles for Cell Type-Preferential Transfection,” ACS Nano 18, no. 42 (2024): 28735–28747.

[110] R. Maharjan, S. Hada, J. E. Lee, et al., “Comparative Study of Lipid Nanoparticle-Based mRNA Vaccine Bioprocess With Machine Learning and Combinatorial Artificial Neural Network-Design of Experiment Approach,” International Journal of Pharmaceutics 640 (2023): 123012.

[111] R. Maharjan, K. H. Kim, K. Lee, H. K. Han, and S. H. Jeong, “Machine Learning-Driven Optimization of mRNA-Lipid Nanoparticle Vaccine Quality With XGBoost/Bayesian Method and Ensemble Model Approaches,” Journal of Pharmaceutical Analysis 14, no. 11 (2024): 100996.

[112] S. Sato, S. Sano, H. Muto, et al., “Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,” Chemical and Pharmaceutical Bulletin 72, no. 6 (2024): 529–539.

[113] S. Moayedpour, J. Broadbent, S. Riahi, et al., “Representations of Lipid Nanoparticles Using Large Language Models for Transfection Efficiency Prediction,” Bioinformatics 40, no. 7 (2024): btae342.

[114] K. Wu, X. Yang, Z. Wang, N. Li, J. Zhang, and L. Liu, “Data-Balanced Transformer for Accelerated Ionizable Lipid Nanoparticles Screening in mRNA Delivery,” Briefings in Bioinformatics 25, no. 3 (2024): bbae186.

[115] T. Henser-Brownhill, L. Martin, P. Samangouei, et al., “In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery,” Adv Sci (Weinh) 11, no. 30 (2024): e2401935.

[116] N. M. Gaudelli, A. C. Komor, H. A. Rees, et al., “Programmable Base Editing of A•T to G•C in Genomic DNA Without DNA Cleavage,” Nature 551, no. 7681 (2017): 464–471.

[117] P. D. Hsu, E. S. Lander, and F. Zhang, “Development and Applications of CRISPR-Cas9 for Genome Engineering,” Cell 157, no. 6 (2014): 1262–1278.

[118] O. Shalem, N. E. Sanjana, E. Hartenian, et al., “Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells,” Science 343, no. 6166 (2014): 84–87.

[119] J. X. Cao, Y. L. Wang, and Z. X. Wang, “Advances in Precise Regulation of CRISPR/Cas9 Gene Editing Technology,” Yi chuan = Hereditas 42, no. 12 (2020): 1168–1177.

[120] X. Xu, C. Liu, Y. Wang, et al., “Nanotechnology-Based Delivery of CRISPR/Cas9 for Cancer Treatment,” Advanced Drug Delivery Reviews 176 (2021): 113891.

[121] K. Suzuki, Y. Tsunekawa, R. Hernandez-Benitez, et al., “In Vivo Genome Editing via CRISPR/Cas9 Mediated Homology-Independent Targeted Integration,” Nature 540, no. 7631 (2016): 144–149.

[122] R. Zheng, L. Zhang, R. Parvin, et al., “Progress and Perspective of CRISPR-Cas9 Technology in Translational Medicine,” Advanced Science 10, no. 25 (2023): e2300195.

[123] H. Yin, C. Q. Song, J. R. Dorkin, et al., “Therapeutic Genome Editing by Combined Viral and Non-Viral Delivery of CRISPR System Components In Vivo,” Nature Biotechnology 34, no. 3 (2016): 328–333.

[124] H. Cheng, X. Yang, H. Si, et al., “Genomic and Transcriptomic Characterization Links Cell Lines With Aggressive Head and Neck Cancers,” Cell Reports 25, no. 5 (2018): 1332–1345.e5.

[125] Y. Jiang, S. Chen, S. Hsiao, et al., “Efficient and Safe In Vivo Treatment of Primary Hyperoxaluria Type 1 via LNP-CRISPR-Cas9-Mediated Glycolate Oxidase Disruption,” Molecular Therapy 33, no. 1 (2025): 104–118.

[126] C. Q. Song, T. Jiang, M. Richter, et al., “Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia,” Nature Biomedical Engineering 4, no. 1 (2020): 125–130.

[127] A. F. Leal, N. Fnu, E. Benincore-Flórez, et al., “The Landscape of CRISPR/Cas9 for Inborn Errors of Metabolism,” Molecular Genetics and Metabolism 138, no. 1 (2023): 106968.

[128] K. Zhang, P. Wan, L. Wang, et al., “Efficient Expansion and CRISPR-Cas9-Mediated Gene Correction of Patient-Derived Hepatocytes for Treatment of Inherited Liver Diseases,” Cell Stem Cell 31, no. 8 (2024): 1187–1202.e8.

[129] M. L. Zhang, H. B. Li, and Y. Jin, “Application and Perspective of CRISPR/Cas9 Genome Editing Technology in Human Diseases Modeling and Gene Therapy,” Frontiers in Genetics 15 (2024): 1364742.

[130] N. Thapar, M. A. F. Eid, N. Raj, T. Kantas, H. S. Billing, and D. Sadhu, “Application of CRISPR/Cas9 in the Management of Alzheimer's Disease and Parkinson's Disease: A Review,” Annals of Medicine & Surgery 86, no. 1 (2024): 329–335.

[131] N. Tang, Y. Zhang, M. Pedrera, et al., “A Simple and Rapid Approach to Develop Recombinant Avian Herpesvirus Vectored Vaccines Using CRISPR/Cas9 System,” Vaccine 36, no. 5 (2018): 716–722.

[132] Q. Mao, Q. Ye, Y. Xu, et al., “Murine Trophoblast Organoids as a Model for Trophoblast Development and CRISPR-Cas9 Screening,” Developmental Cell 58, no. 24 (2023): 2992–3008.e7.

[133] E. Dreano, M. Bacchetta, J. Simonin, et al., “Characterization of Two Rat Models OF Cystic Fibrosis: F508DEL and KO CFTR Generated by Crispr-Cas9,” Pediatric Pulmonology 54 (2019): S318–S319.

[134] X. Hu, “CRISPR/Cas9 System and Its Applications in Human Hematopoietic Cells,” Blood Cells, Molecules, and Diseases 62 (2016): 6–12.

[135] A. C. Komor, Y. B. Kim, M. S. Packer, J. A. Zuris, and D. R. Liu, “Programmable Editing of a Target Base in Genomic DNA Without Double-Stranded DNA Cleavage,” Nature 533, no. 7603 (2016): 420–424.

[136] M. A. Coelho, M. E. Strauss, A. Watterson, et al., “Base Editing Screens Define the Genetic Landscape of Cancer Drug Resistance Mechanisms,” Nature Genetics 56, no. 11 (2024): 2479–2492.

[137] T. Rothgangl, M. K. Dennis, P. J. C. Lin, et al., “In Vivo Adenine Base Editing of PCSK9 in Macaques Reduces LDL Cholesterol Levels,” Nature Biotechnology 39, no. 8 (2021): 949–957.

[138] Y. Xu, C. Chen, Y. Guo, S. Hu, and Z. Sun, “Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy,” Frontiers in Immunology 13 (2022): 848327.

[139] M. Y. Park, M. H. Jung, E. Y. Eo, et al., “Generation of Lung Cancer Cell Lines Harboring EGFR T790M Mutation by CRISPR/Cas9-Mediated Genome Editing,” Oncotarget 8, no. 22 (2017): 36331–36338.

[140] A. Mei, K. P. Letscher, and S. Reddy, “Engineering Next-Generation Chimeric Antigen Receptor-T Cells: Recent Breakthroughs and Remaining Challenges in Design and Screening of Novel Chimeric Antigen Receptor Variants,” Current Opinion in Biotechnology 90 (2024): 103223.

[141] M. Qiu, Z. Glass, J. Chen, et al., “Lipid Nanoparticle-Mediated Codelivery of Cas9 mRNA and Single-Guide RNA Achieves Liver-Specific In Vivo Genome Editing of Angptl3,” Proceedings of the National Academy of Sciences 118, no. 10 (2021): e2020401118.

[142] B. W. Thuronyi, L. W. Koblan, J. M. Levy, et al., “Continuous Evolution of Base Editors With Expanded Target Compatibility and Improved Activity,” Nature Biotechnology 37, no. 9 (2019): 1070–1079.

[143] Y. K. Jeong, B. Song, and S. Bae, “Current Status and Challenges of DNA Base Editing Tools,” Molecular Therapy 28, no. 9 (2020): 1938–1952.

[144] O. O. Abudayyeh, J. S. Gootenberg, B. Franklin, et al., “A Cytosine Deaminase for Programmable Single-Base RNA Editing,” Science 365, no. 6451 (2019): 382–386.

[145] D. B. T. Cox, J. S. Gootenberg, O. O. Abudayyeh, et al., “RNA Editing With CRISPR-Cas13,” Science 358, no. 6366 (2017): 1019–1027.

[146] S. Mitschka and C. Mayr, “Context-Specific Regulation and Function of mRNA Alternative Polyadenylation,” Nature Reviews Molecular Cell Biology 23, no. 12 (2022): 779–796.

[147] J. A. Kulkarni, D. Witzigmann, S. B. Thomson, et al., “The Current Landscape of Nucleic Acid Therapeutics,” Nature Nanotechnology 16, no. 6 (2021): 630–643.

[148] X. Liu, P. Huang, R. Yang, and H. Deng, “mRNA Cancer Vaccines: Construction and Boosting Strategies,” ACS Nano 17, no. 20 (2023): 19550–19580.

[149] S. Castillo-Hair, S. Fedak, B. Wang, et al., “Optimizing 5'UTRs for mRNA-Delivered Gene Editing Using Deep Learning,” Nature Communications 15, no. 1 (2024): 5284.

[150] A. G. Orlandini von Niessen, M. A. Poleganov, C. Rechner, et al., “Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3’ UTRs Identified by Cellular Library Screening,” Molecular Therapy 27, no. 4 (2019): 824–836.

[151] K. D. Nance and J. L. Meier, “Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines,” ACS Central Science 7, no. 5 (2021): 748–756.

[152] J. K. Nuñez, J. Chen, G. C. Pommier, et al., “Genome-Wide Programmable Transcriptional Memory by CRISPR-Based Epigenome Editing,” Cell 184, no. 9 (2021): 2503–2519.e17.

[153] P. Stepper, G. Kungulovski, R. Z. Jurkowska, et al., “Efficient Targeted DNA Methylation With Chimeric dCas9-Dnmt3a-Dnmt3L Methyltransferase,” Nucleic Acids Research 45, no. 4 (2017): 1703–1713.

[154] X. S. Liu, H. Wu, X. Ji, et al., “Editing DNA Methylation in the Mammalian Genome,” Cell 167, no. 1 (2016): 233–247.e17.

[155] H. Shi, Y. Xu, N. Tian, M. Yang, and F. S. Liang, “Inducible and Reversible RNA N(6)-Methyladenosine Editing,” Nature Communications 13, no. 1 (2022): 1958.

[156] C. Wilson, P. J. Chen, Z. Miao, and D. R. Liu, “Programmable m(6)A Modification of Cellular RNAs With a Cas13-Directed Methyltransferase,” Nature Biotechnology 38, no. 12 (2020): 1431–1440.

[157] L. Yu, M. Alariqi, B. Li, et al., “CRISPR/dCas13(Rx) Derived RNA N(6)-Methyladenosine (m(6)A) Dynamic Modification in Plant,” Advanced Science 11, no. 39 (2024): e2401118.

[158] F. Tremblay, K. Kelly, S. Shah, et al., “Development of a Human PCSK9-Targeting Epigenetic Editor With Durable, Near-Complete In Vivo Silencing Efficiency,” Molecular Therapy 31, no. 4 (2023): 84–85.

[159] E. Haghighi, S. S. Abolmaali, A. Dehshahri, S. A. Mousavi Shaegh, N. Azarpira, and A. M. Tamaddon, “Navigating the Intricate In-Vivo Journey of Lipid Nanoparticles Tailored for the Targeted Delivery of RNA Therapeutics: A Quality-by-Design Approach,” Journal of Nanobiotechnology 22, no. 1 (2024): 710.

[160] R. Chu, Y. Wang, J. Kong, T. Pan, Y. Yang, and J. He, “Lipid Nanoparticles as the Drug Carrier for Targeted Therapy of Hepatic Disorders,” Journal of Materials Chemistry B 12, no. 20 (2024): 4759–4784.

[161] J. Du, Q. Wu, C. Liu, N. Wang, and C. Gong, “CRISPR Delivery Systems for Organ-Specific Targeting: Advances and Challenges,” Precision Medicine and Engineering 2, no. 4 (2025): 100048.

[162] L. N. Kasiewicz, S. Biswas, A. Beach, et al., “GalNAc-Lipid Nanoparticles Enable Non-LDLR Dependent Hepatic Delivery of a CRISPR Base Editing Therapy,” Nature Communications 14, no. 1 (2023): 2776.

[163] F. Wu, N. Li, Y. Xiao, et al., “Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components,” Small Methods 10, no. 2 (2025): e2401632.

[164] M. Prakash, C. D. Cortez, A. Jayaraman, et al., “Innovative Gene Engineering and Drug Delivery Systems for Dendritic Cells in Cancer Immunotherapy,” Journal of Biomedical Science 32, no. 1 (2025): 95.

[165] Z. Sethna, P. Guasp, C. Reiche, et al., “RNA Neoantigen Vaccines Prime Long-Lived CD8(+) T Cells in Pancreatic Cancer,” Nature 639, no. 8056 (2025): 1042–1051.

[166] Z. Liu, Z. Li, and B. Li, “Nonviral Delivery of CRISPR/Cas Systems in mRNA Format,” Advanced NanoBiomed Research 2, no. 11 (2022): 2200082.

[167] M. Kim, M. Go, S. H. Kang, S. Jeong, and K. Lim, “Revolutionizing CRISPR Technology With Artificial Intelligence,” Experimental & Molecular Medicine 57, no. 7 (2025): 1419–1431.

[168] R. G. Lee, A. M. Mazzola, M. C. Braun, et al., “Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models,” Circulation 147, no. 3 (2023): 242–253.

[169] P. Flight, E. Rohde, R. Lee, et al., “VERVE-102, a Clinical Stage In Vivo Base Editing Medicine, Leads to Potent and Precise Inactivation of PCSK9 in Preclinical Studies,” Journal of Clinical Lipidology 19, no. 3, Suppl (2025): e68.

[170] R. Lee, A. Mazzola, J. Denizio, et al., “An Investigational In Vivo Base Editing Medicine Targeting ANGPTL3, VERVE-201, Achieves Precise and Durable Liver Editing in Nonclinical Studies,” Atherosclerosis 395 (2024): 118496.

[171] R. Lee, J. Denizio, C. Dutta, et al., “Preclinical Data Supporting Potential Efficacy of VERVE-201 – An Investigational CRISPR Base Editing Medicine Targeting ANGPTL3 – In Primary Human Cells, Mice, and Non-Human Primates,” Journal of the American College of Cardiology 81, no. 8_Suppl (2023): 1115.

[172] I. Arnaoutova, Y. Aratyn-Schaus, L. Zhang, et al., “Base-Editing Corrects Metabolic Abnormalities in a Humanized Mouse Model for Glycogen Storage Disease Type-Ia,” Nature Communications 15, no. 1 (2024): 9729.

[173] J. D. Gillmore, E. Gane, J. Taubel, et al., “CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis,” New England Journal of Medicine 385, no. 18 (2021): 1721–1723.

[174] D. M. Cohn, P. Gurugama, M. Magerl, et al., “CRISPR-Based Therapy for Hereditary Angioedema,” New England Journal of Medicine 392, no. 5 (2025): 458–467.

[175] T. Horie and K. Ono, “VERVE-101: A Promising CRISPR-Based Gene Editing Therapy That Reduces LDL-C and PCSK9 Levels in HeFH Patients,” European Heart Journal - Cardiovascular Pharmacotherapy 10, no. 2 (2024): 89–90.

[176] S. B. Vafai, J. Täubel, T. Ashdown, et al., “In Vivo Base Editing of PCSK9 With VERVE-102 for Hypercholesterolemia,” New England Journal of Medicine (2026): oa2601283, https://doi.org/10.1056/NEJMoa2601283.

[177] R. Lee, J. Denizio, T. Mizoguchi, et al., “An Investigational In Vivo Base Editing Medicine Targeting ANGPTL3, VERVE-201, Achieves Potent and LDLR-Independent Liver Editing in Mouse Models,” European Heart Journal 44, no. Suppl_2 (2023): ehad655.2521.

[178] Y. Jiang, L. Huang, H. Qiu, et al., “Clinical Safety and Tolerability of In Vivo Gene Editing Drug ART001 for ATTR Amyloidosis,” Frontiers in Medicine 13 (2026): 1783921.

[179] L. J. Laffin, S. J. Nicholls, R. S. Scott, et al., “Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3,” New England Journal of Medicine 393, no. 21 (2025): 2119–2130.

[180] Y. Sun, Y. Wu, Z. He, et al., “Type III CRISPR-Mediated Flexible RNA Excision With Engineered Guide RNAs,” Molecular Cell 85, no. 5 (2025): 989–998.e4.

[181] B. P. Kleinstiver, M. S. Prew, S. Q. Tsai, et al., “Engineered CRISPR-Cas9 Nucleases With Altered PAM Specificities,” Nature 523, no. 7561 (2015): 481–485.

[182] D. Wang, C. Zhang, B. Wang, et al., “Optimized CRISPR Guide RNA Design for Two High-Fidelity Cas9 Variants by Deep Learning,” Nature Communications 10, no. 1 (2019): 4284.

[183] H. K. Kim, S. Min, M. Song, et al., “Deep Learning Improves Prediction of CRISPR-Cpf1 Guide RNA Activity,” Nature Biotechnology 36, no. 3 (2018): 239–241.

[184] G. Chuai, H. Ma, J. Yan, et al., “DeepCRISPR: Optimized CRISPR Guide RNA Design by Deep Learning,” Genome Biology 19, no. 1 (2018): 80.

[185] A. Tsherniak, F. Vazquez, P. G. Montgomery, et al., “Defining a Cancer Dependency Map,” Cell 170, no. 3 (2017): 564–576.e16.

[186] G. X. Y. Zheng, J. M. Terry, P. Belgrader, et al., “Massively Parallel Digital Transcriptional Profiling of Single Cells,” Nature Communications 8 (2017): 14049.

[187] H. H. Wessels, A. Stirn, A. Méndez-Mancilla, et al., “Prediction of on-Target and Off-Target Activity of CRISPR-Cas13d Guide RNAs Using Deep Learning,” Nature Biotechnology 42, no. 4 (2024): 628–637.

[188] M. Stemmer, T. Thumberger, M. Del Sol Keyer, J. Wittbrodt, and J. L. Mateo, “CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool,” PLoS One 10, no. 4 (2015): e0124633.

[189] D. Anderson, J. Witten, Using Artificial Intelligence to Develop Gene Therapy for the Lungs,” Nature Biotechnology 43 (2024): 1768–1769.

[190] L. Chen, T. Jiao, W. Liu, et al., “Hepatic Cytochrome P450 8B1 and Cholic Acid Potentiate Intestinal Epithelial Injury in Colitis by Suppressing Intestinal Stem Cell Renewal,” Cell Stem Cell 29, no. 9 (2022): 1366–1381.e9.

[191] R. Alipanahi, L. Safari, and A. Khanteymoori, “DTMP-Prime: A Deep Transformer-Based Model for Predicting Prime Editing Efficiency and PegRNA Activity,” Molecular Therapy. Nucleic Acids 35, no. 4 (2024): 102370.

[192] S. L. Shipman, J. Nivala, J. D. Macklis, and G. M. Church, “CRISPR-Cas Encoding of a Digital Movie Into the Genomes of a Population of Living Bacteria,” Nature 547, no. 7663 (2017): 345–349.

[193] Z. Chen, R. D. Kibler, A. Hunt, et al., “De Novo Design of Protein Logic Gates,” Science 368, no. 6486 (2020): 78–84.

[194] S. Xu, D. Liang, Q. Wang, et al., “In Vivo Genome Editing of Human Haematopoietic Stem Cells for Treatment of Blood Disorders Using mRNA Delivery,” Nature Biomedical Engineering 10 (2025): 473–489.

[195] K. Onomoto, K. Onoguchi, and M. Yoneyama, “Regulation of RIG-I-Like Receptor-Mediated Signaling: Interaction Between Host and Viral Factors,” Cellular & Molecular Immunology 18, no. 3 (2021): 539–555.

[196] D. Zheng, L. Persyn, J. Wang, et al., “Predicting the Translation Efficiency of Messenger RNA in Mammalian Cells,” Nature Biotechnology 44 (2025): 783–796.

[197] X. Fan, T. Chang, C. Chen, M. Hafner, and Z. Wang, “Analysis of RNA Translation With a Deep Learning Architecture Provides New Insight Into Translation Control,” Nucleic Acids Research 53, no. 7 (2025): gkaf277.

[198] E. L. Van Nostrand, P. Freese, G. A. Pratt, et al., “A Large-Scale Binding and Functional Map of Human RNA-Binding Proteins,” Nature 583, no. 7818 (2020): 711–719.

[199] J. Kweon, J. K. Yoon, A. H. Jang, et al., “Engineered Prime Editors With PAM Flexibility,” Molecular Therapy 29, no. 6 (2021): 2001–2007.

[200] J. R. Hamilton, C. A. Tsuchida, D. N. Nguyen, et al., “Targeted Delivery of CRISPR-Cas9 and Transgenes Enables Complex Immune Cell Engineering,” Cell Reports 35, no. 9 (2021): 109207.

[201] S. Liu, Q. Cheng, T. Wei, et al., “Membrane-Destabilizing Ionizable Phospholipids for Organ-Selective mRNA Delivery and CRISPR-Cas Gene Editing,” Nature Materials 20, no. 5 (2021): 701–710.

[202] J. D. Finn, A. R. Smith, M. C. Patel, et al., “A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing,” Cell Reports 22, no. 9 (2018): 2227–2235.

[203] J. Walther, D. Porenta, D. Wilbie, et al., “Comparative Analysis of Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for Gene Editing in Vitro and In Vivo,” European Journal of Pharmaceutics and Biopharmaceutics 196 (2024): 114207.

[204] X. Hou, T. Zaks, R. Langer, and Y. Dong, “Lipid Nanoparticles for mRNA Delivery,” Nature Reviews Materials 6, no. 12 (2021): 1078–1094.

[205] A. Omer-Javed, G. Pedrazzani, L. Albano, et al., “Mobilization-Based Chemotherapy-Free Engraftment of Gene-Edited Human Hematopoietic Stem Cells,” Cell 185, no. 13 (2022): 2248–2264.e21.

[206] L. Cui, S. Pereira, S. Sonzini, et al., “Development of a High-Throughput Platform for Screening Lipid Nanoparticles for mRNA Delivery,” Nanoscale 14, no. 4 (2022): 1480–1491.

[207] J. Tycko, V. E. Myer, and P. D. Hsu, “Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity,” Molecular Cell 63, no. 3 (2016): 355–370.

[208] B. Alipanahi, A. Delong, M. T. Weirauch, and B. J. Frey, “Predicting the Sequence Specificities of DNA- and RNA-Binding Proteins by Deep Learning,” Nature Biotechnology 33, no. 8 (2015): 831–838.

[209] W. N. Price and I. G. Cohen, “Privacy in the Age of Medical Big Data,” Nature Medicine 25, no. 1 (2019): 37–43.

[210] D. S. Char, N. H. Shah, and D. Magnus, “Implementing Machine Learning in Health Care - Addressing Ethical Challenges,” New England Journal of Medicine 378, no. 11 (2018): 981–983.

[211] T. Hofweber and R. L. Walker, “Machine Learning in Health Care: Ethical Considerations Tied to Privacy, Interpretability, and Bias,” North Carolina Medical Journal 85, no. 4 (2024): 240–245.

[212] B. Z. Sun, “Review of Altered Inheritance: CRISPR and the Ethics of Human Genome Editing by Françoise Baylis,” Monash Bioethics Review 38, no. 1 (2020): 91–93.

[213] M. Ortiz-Bueno, F. Zinghirino, P. P. Serra, et al., “From Bench to Bedside: Ethical and Clinical Best Practices for Genome Editing Applications,” International Journal of Molecular Sciences 27, no. 3 (2026): 1484.

Rights & permissions

2026 The Author(s). MedComm - Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).